Jeffrey Hafkin

632 total citations
16 papers, 237 citations indexed

About

Jeffrey Hafkin is a scholar working on Infectious Diseases, Epidemiology and Molecular Biology. According to data from OpenAlex, Jeffrey Hafkin has authored 16 papers receiving a total of 237 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Infectious Diseases, 8 papers in Epidemiology and 5 papers in Molecular Biology. Recurrent topics in Jeffrey Hafkin's work include Tuberculosis Research and Epidemiology (10 papers), Cancer therapeutics and mechanisms (5 papers) and Pneumocystis jirovecii pneumonia detection and treatment (5 papers). Jeffrey Hafkin is often cited by papers focused on Tuberculosis Research and Epidemiology (10 papers), Cancer therapeutics and mechanisms (5 papers) and Pneumocystis jirovecii pneumonia detection and treatment (5 papers). Jeffrey Hafkin collaborates with scholars based in United States, South Africa and Japan. Jeffrey Hafkin's co-authors include Lawrence Geiter, Rajesh Gupta, Yongge Liu, Makoto Matsumoto, Masuhiro Yoshitake, Norbert Hittel, Emily A. Blumberg, Chawangwa Modongo, Elizabeth D. Lowenthal and Andrew P. Steenhoff and has published in prestigious journals such as Gastroenterology, Journal of the American Society of Nephrology and Antimicrobial Agents and Chemotherapy.

In The Last Decade

Jeffrey Hafkin

15 papers receiving 231 citations

Peers

Countries citing papers authored by Jeffrey Hafkin

Since Specialization

Citations

This map shows the geographic impact of Jeffrey Hafkin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jeffrey Hafkin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jeffrey Hafkin more than expected).

Fields of papers citing papers by Jeffrey Hafkin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jeffrey Hafkin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jeffrey Hafkin. The network helps show where Jeffrey Hafkin may publish in the future.

Co-authorship network of co-authors of Jeffrey Hafkin

This figure shows the co-authorship network connecting the top 25 collaborators of Jeffrey Hafkin. A scholar is included among the top collaborators of Jeffrey Hafkin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jeffrey Hafkin. Jeffrey Hafkin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

#	Work	Indexed citations
1	Evaluating Sibeprenlimab in IgA Nephropathy - Rationale and Baseline Data from the VISIONARY Trial 2025 ·Kidney International Reports ·Vlado Perkovic, Jonathan Barratt, Richard Lafayette, Adrian Liew, Yusuke Suzuki, Kevin Carroll, Chee Kay Cheung, Vladimı́r Tesař, Hernán Trimarchi, Muh Geot Wong, Hong Zhang, Jing Xia, (unknown), (unknown), Jeffrey Hafkin, Dana V. Rizk	0
2	WCN25-499 PATIENT BASELINE CHARACTERISTICS IN THE ONGOING PHASE 3 VISIONARY TRIAL: A RANDOMIZED, PLACEBO-CONTROLLED STUDY OF SIBEPRENLIMAB FOR IMMUNOGLOBULIN A NEPHROPATHY 2025 ·Kidney International Reports ·Richard Lafayette, Hernán Trimarchi, Jonathan Barratt, Kevin Carroll, Vladimı́r Tesař, Hong Zhang, Yusuke Suzuki, Adrian Liew, Muh Geot Wong, (unknown), Jing Xia, (unknown), Jeffrey Hafkin, Vlado Perkovic	2
3	Safety, pharmacokinetics, and early bactericidal activity of quabodepistat in combination with delamanid, bedaquiline, or both in adults with pulmonary tuberculosis: a randomised, active-controlled, open-label trial 2024 ·The Lancet Infectious Diseases ·Rodney Dawson, Andreas H. Diacon, Veronique de Jager, Kim Narunsky, Vineshree Mischka Moodley, (unknown), Yongge Liu, Bo Zheng, Jeffrey Hafkin	4
4	Quabodepistat in combination with delamanid and bedaquiline in participants with drug-susceptible pulmonary tuberculosis: protocol for a multicenter, phase 2b/c, open-label, randomized, dose-finding trial to evaluate safety and efficacy 2024 ·Trials ·Rodney Dawson, Andreas H. Diacon, Simbarashe Takuva, Yongge Liu, Bo Zheng, Vatsala Karwe, Jeffrey Hafkin	3
5	Phase I Single Ascending Dose and Food Effect Study in Healthy Adults and Phase I/IIa Multiple Ascending Dose Study in Patients with Pulmonary Tuberculosis to Assess Pharmacokinetics, Bactericidal Activity, Tolerability, and Safety of OPC-167832 2023 ·Antimicrobial Agents and Chemotherapy ·Rodney Dawson, Andreas H. Diacon, Kim Narunsky, Veronique de Jager, (unknown), Xiaoyan Zhang, Yongge Liu, Jeffrey Hafkin	7
6	A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Sibeprenlimab Administered Subcutaneously in Patients With IgA Nephropathy 2022 ·Journal of the American Society of Nephrology ·Dana V. Rizk, Vlado Perkovic, Richard Lafayette, Hernán Trimarchi, Jonathan Barratt, Kevin Carroll, Vladimı́r Tesař, Hong Zhang, Yusuke Suzuki, Adrian Liew, Muh Geot Wong, Bruce R. Leslie, Mohit Mathur, Jeffrey Hafkin	2
7	Delamanid Added to an Optimized Background Regimen in Children with Multidrug-Resistant Tuberculosis: Results of a Phase I/II Clinical Trial 2022 ·Antimicrobial Agents and Chemotherapy ·Anthony J. Garcia‐Prats, (unknown), (unknown), (unknown), Maria Tarcela Gler, H. Simon Schaaf, Anneke C. Hesseling, (unknown), Jeffrey Hafkin	14
8	Cumulative Fraction of Response for Once- and Twice-Daily Delamanid in Patients with Pulmonary Multidrug-Resistant Tuberculosis 2020 ·Antimicrobial Agents and Chemotherapy ·Suresh Mallikaarjun, Moti Chapagain, T. Sasaki, Norimitsu Hariguchi, Devyani Deshpande, Shashikant Srivastava, Alexander Berg, (unknown), Yusuke Inoue, Makoto Matsumoto, Jeffrey Hafkin, Lawrence Geiter, Xiaofeng Wang, Tawanda Gumbo, Yongge Liu	17
9	Compassionate use of delamanid in adults and children for drug-resistant tuberculosis: 5-year update 2020 ·European Respiratory Journal ·(unknown), Lusine Breitscheidel, (unknown), Alexandra Martin, Jeffrey Hafkin, Norbert Hittel	8
10	Delamanid: From discovery to its use for pulmonary multidrug-resistant tuberculosis (MDR-TB) 2018 ·Tuberculosis ·Yongge Liu, Makoto Matsumoto, (unknown), (unknown), Masuhiro Yoshitake, Rajesh Gupta, Lawrence Geiter, Jeffrey Hafkin	113
11	Delamanid in the treatment of multidrug-resistant tuberculosis 2016 ·The International Journal of Tuberculosis and Lung Disease ·Rajesh Gupta, Charles D. Wells, Norbert Hittel, Jeffrey Hafkin, Lawrence Geiter	16
12	Incidence and risk factors for incomplete HBV DNA suppression in HIV/HBV‐co‐infected patients initiating tenofovir‐based therapy 2013 ·Journal of Viral Hepatitis ·Jeffrey Hafkin, Melissa Osborn, A. Russell Localio, Valerianna Amorosa, Jay R. Kostman, John J. Stern, (unknown), Karam Mounzer, Ian Frank, Robert Gross, Kyong‐Mi Chang, Vincent Lo Re	18
13	Impact of the human immunodeficiency virus on early multidrug-resistant tuberculosis treatment outcomes in Botswana 2013 ·The International Journal of Tuberculosis and Lung Disease ·Jeffrey Hafkin, Chawangwa Modongo, Craig Newcomb, Elizabeth D. Lowenthal, Rob Roy MacGregor, Andrew P. Steenhoff, Harvey M. Friedman, (unknown)	20
14	Sa1966 A Comparison of the Clinical and Immunological Characteristics in Patients With Acute Hepatitis C With and Without HIV-Coinfection 2012 ·Gastroenterology ·Jeffrey Hafkin, Masahiro Kikuchi, (unknown), Mary E. Valiga, Frederick A. Nunes, Valerianna Amorosa, Karam Mounzer, David E. Kaplan, Ian Frank, Pablo Tebas, K. Rajender Reddy, Ayse Aytaman, Andrea D. Branch, Daniel S. Fierer, (unknown)	1
15	Drug-Resistant Tuberculosis in Sub-Saharan Africa 2010 ·Current Infectious Disease Reports ·Jeffrey Hafkin, Victoria M. Gammino, Joseph J Amon	5
16	Infections in lung transplantation: new insights 2009 ·Current Opinion in Organ Transplantation ·Jeffrey Hafkin, Emily A. Blumberg	7

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact